By Dean Seal
CytomX Therapeutics said it would reduce its organizational headcount by about 40%, primarily affecting staff in general and administrative functions.
The oncology-focused biopharma company said Monday the job cuts are expected to extend its cash runway into the second quarter of 2026.
CytomX expects the restructuring to cost about $5 million to $6 million. The charges will be recorded in the first quarter of this year, when the layoffs are expected to be substantially completed. The costs are related to one-time termination severance payments.
The smaller workforce that remains will prioritize CX-2051, CytomX's tumor-fighting drug candidate.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
January 06, 2025 17:26 ET (22:26 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.